Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study.
BACKGROUND
Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD.


RESULTS
The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade ≥3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) and 7·4% (95% CI, 6.2-8.9) when only the CDs of grade ≥3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1-48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4-163.0) in those who had received no anthracycline and an HRD≥30Gy, and 61.5 (95% CI, 19.6-192.8) in those who had received both anthracycline and an HRD≥30Gy.


CONCLUSIONS
Survivors of childhood cancers treated with radiotherapy and anthracycline run a high dose-dependent risk of developing CD. CDs develop earlier in patients treated with anthracycline than in those treated without it.
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.). nadia.haddy@gustaveroussy.fr.
Nadia
N
Haddy
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Stéphanie
S
Diallo
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Chiraz
C
El-Fayech
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Boris
B
Schwartz
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
François
F
Pein
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Mike
M
Hawkins
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Cristina
C
Veres
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Odile
O
Oberlin
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Catherine
C
Guibout
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Hélène
H
Pacquement
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Martine
M
Munzer
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Tan Dat
TD
N'Guyen
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Pierre-Yves
PY
Bondiau
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Delphine
D
Berchery
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Anne
A
Laprie
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Pierre-Yves
PY
Scarabin
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Xavier
X
Jouven
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
André
A
Bridier
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Serge
S
Koscielny
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Eric
E
Deutsch
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Ibrahima
I
Diallo
From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Florent
F
de Vathaire
D000328:Adult; D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D024221:Antineoplastic Protocols; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy*; D012307:Risk Factors
D018943:Anthracyclines; D000970:Antineoplastic Agents
anthracycline; childhood cancer; cohort studies; heart diseases; radiotherapy